TL;DR
This study systematically evaluated Trop-2 expression in solid tumors using both immunohistochemistry (IHC) and mass spectrometry (MS) within a molecular tumor board (MTB) setting. The findings suggest that Trop-2 expression analysis is valuable for guiding personalized treatment decisions, particularly for off-label ADC therapies, and highlights the potential of multi-omics approaches for biomarker assessment.
What Problem Does This Paper Address?
The development of personalized cancer therapies, especially those utilizing antibody-drug conjugates (ADCs), is often hampered by a lack of reliable predictive biomarkers. While Trop-2 is a promising target for ADCs, its expression varies across different tumor types, and a standardized, validated method for its assessment in a broad range of solid tumors is needed. This paper addresses the challenge of accurately determining Trop-2 expression to inform treatment decisions within the complex, interdisciplinary setting of a molecular tumor board, where patients often have exhausted standard treatment options.
Methods
The researchers employed a two-pronged approach to assess Trop-2 expression:
- Immunohistochemistry (IHC): Formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples were stained using the Trop-2 antibody clone EPR20043. Expression levels were quantified using an H-score, categorizing tumors into "negative," "low," "moderate," and "high" expression. This is a standard method for protein detection in tissue.
- Mass Spectrometry (MS)-based Proteomics: For a subset of samples, MS was used to quantify Trop-2 protein levels. This technique offers a more objective and potentially broader detection of the protein, as it can identify multiple peptides and is less dependent on specific antibody epitopes. The MS data was used to correlate with IHC results and validate the IHC findings.
The study also involved a retrospective analysis of patient data from the Freiburg Molecular Tumorboard (MTB), including treatment recommendations made based on Trop-2 expression.
Datasets
The study utilized a cohort of 50 patients from the Comprehensive Cancer Center Freiburg (CCCF) who presented at the Molecular Tumorboard (MTB). These patients had advanced or progressive tumors after exhausting standard therapies. For 22 of these patients, MS-based proteomics was also performed. The data was collected between October 2023 and January 2024.
Key Insights and Ideas
- Trop-2 as a Key Biomarker for ADC Therapy: The study reinforces Trop-2's importance as a target for ADCs, particularly in solid tumors where other predictive biomarkers may be lacking.
- Validation of IHC with MS: The positive correlation between IHC and MS-based Trop-2 quantification is a crucial finding. It validates the reliability of IHC for Trop-2 assessment in clinical practice, while also highlighting the complementary power of MS for deeper proteomic insights.
- MTB Utility for Off-Label Decisions: The findings underscore the value of Trop-2 expression analysis within the MTB setting for guiding off-label therapeutic recommendations, especially for ADCs where approved indications may not cover all patient scenarios.
- Potential for Predictive and Prognostic Value: Beyond ADC therapy, the study hints at Trop-2's potential as a prognostic marker (e.g., in relation to checkpoint inhibitor resistance), suggesting broader implications for its clinical utility.
- Multi-Omics Promise: The successful integration of IHC and MS data points towards the future of personalized medicine, where combining different "omics" data layers can provide a more comprehensive understanding of tumor biology and treatment response.
Key Results
- Expression Levels: Trop-2 expression was found to be:
- Negative in 16% of cases.
- Low in 20% of cases.
- Moderate in 18% of cases.
- High in 46% of cases.
- Correlation: A positive correlation (Pearson correlation coefficient of 0.48) was observed between Trop-2 IHC scores and MS-based protein intensities, validating the IHC method.
- Treatment Recommendations:
- Treatment recommendations for a Trop-2 ADC were given in 61% of cases.
- Trop-2 ADC was considered the highest priority therapeutic approach in 20% of cases.
- Tumor Type Differences: Certain tumor types, such as breast and urothelial carcinomas, consistently showed high or moderate Trop-2 expression, while skin tumors were largely negative, and colorectal tumors showed low expression.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Cohort Size: While 50 cases were analyzed for IHC, the MS-based analysis was performed on a smaller subset (22 cases), and the correlation analysis for MS-identified Trop-2 was based on 19 cases. Larger cohorts are needed to strengthen statistical power.
- Antibody Specificity: While the study used a specific antibody clone (EPR20043), the immunogenicity of the epitope can be a "trade secret" for ADC development, and the study acknowledges that the antibody used for diagnostics might not always be the same as that used for therapy.
- Correlation Nuances: The linear regression for the correlation analysis showed an extended confidence interval due to the limited sample size.
- Future Directions:
- Larger Cohorts: Expanding the study population is crucial for more robust conclusions.
- Correlation with Treatment Response: Further studies are needed to correlate Trop-2 expression levels with actual therapeutic response to Trop-2 ADCs.
- Genomic and Other Biomarker Correlations: Investigating the relationship between Trop-2 expression and genomic tumor phenotypes, as well as response to immunotherapies (like checkpoint inhibitors) or other treatments, is a key area for future research.
- Independent Validation: Publishing objective results through independent, non-profit organizations is suggested to enhance transparency and trust.
Summary updated